1. Home
  2. RNTX vs CNF Comparison

RNTX vs CNF Comparison

Compare RNTX & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

CNF

CNFinance Holdings Limited each representing twenty (20)

N/A

Current Price

$2.99

Market Cap

53.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
CNF
Founded
2001
1999
Country
United States
China
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
53.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RNTX
CNF
Price
$1.02
$2.99
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
841.5K
7.8K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$252.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$0.37
52 Week High
$2.18
$24.00

Technical Indicators

Market Signals
Indicator
RNTX
CNF
Relative Strength Index (RSI) 39.26 46.98
Support Level N/A $2.69
Resistance Level $1.33 $3.72
Average True Range (ATR) 0.08 0.31
MACD 0.01 0.01
Stochastic Oscillator 24.94 20.00

Price Performance

Historical Comparison
RNTX
CNF

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.

Share on Social Networks: